Soleimani Maryam, Kollmannsberger Christian, Nappi Lucia
BC Cancer, Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Curr Oncol Rep. 2022 Apr;24(4):437-442. doi: 10.1007/s11912-022-01231-1. Epub 2022 Feb 10.
This review will focus on biomarkers in testicular germ cell tumors (TGCT), focusing on microRNAs with high potential clinical application to drive management of TGCT. We explore the mechanism of action of microRNAs, literature to date, and how microRNAs may be incorporated into clinical practice in the near future.
MicroRNAs are small non-coding RNAs found in blood which play an important role in post-transcriptional gene regulation and have been explored in TGCT for the past 15 years. More recently, results show they are promising biomarkers for diagnosis with impressive sensitivity and specificity, while also being cost-effective. MicroRNAs will likely play a critical role in areas of unmet need in GCT in the next decade, as they have many of the characteristics of an ideal biomarker. Ongoing prospective clinical trials evaluating microRNA-371 will be eagerly awaited and will help inform decision-making in real-world application.
本综述将聚焦于睾丸生殖细胞肿瘤（TGCT）中的生物标志物，重点关注具有高临床应用潜力以推动TGCT管理的微小RNA。我们探讨微小RNA的作用机制、迄今为止的文献，以及微小RNA在不久的将来如何纳入临床实践。
微小RNA是血液中发现的小非编码RNA，在转录后基因调控中起重要作用，在过去15年中已在TGCT中进行了研究。最近，结果表明它们是具有令人印象深刻的敏感性和特异性的诊断有前景的生物标志物，同时成本效益也高。微小RNA在下一个十年可能会在生殖细胞肿瘤未满足需求的领域发挥关键作用，因为它们具有理想生物标志物的许多特征。评估微小RNA-371的正在进行的前瞻性临床试验将备受期待，并将有助于为实际应用中的决策提供信息。
